openPR Logo
Press release

Generic drug market in Central Europe will grow by 6% per annum between 2011 and 2013

02-14-2011 03:40 PM CET | Health & Medicine

Press release from: PMR Ltd. Sp. z o.o.

In 2010 the generic drug market in Central Europe increased by 12%, whereas that of original medicines grew at a rate of around 10% in euro terms, according to information contained in the latest report by PMR, a research and consulting company, entitled “Generic and innovative drug market in Central Europe 2011”. In 2011 and 2012 the trends which boosted generic sales in 2010, including price pressure and other restrictive measures, will continue. This is why the generic market will develop more rapidly than its original counterpart during these years.

Generic growth rate will exceed that of originals
No significant increase in the share of innovative medicines is expected in the very near future, because in 2009 and 2010 governments in Central European countries (Poland, Romania, Bulgaria, Hungary, Slovakia and the Czech Republic) were aiming to boost generic consumption and therefore limit national spending on more expensive innovative medicines.
For example, in Bulgaria the innovative pharmaceutical manufacturers (24 companies belonging to the Association of Research-Based Pharmaceutical Manufacturers) agreed to offer a 5% discount on all drugs for which the NHIF pays between June and December 2010. If all pharmaceutical manufacturers adhered to this agreement, this would save the NHIF approximately BGN 1.5m (€0.7m) per month.
In the Czech Republic in 2009 the State Institute for Drug Control (SUKL) concentrated on changes to ex-factory prices for reimbursement medicines. Maximum prices were reduced for 390 SUKL codes, and increased for 190 SUKL codes. The SUKL expected to save CZK 2.4bn (€94.9m) by means of the revision of the prices of 1,270 reimbursed drugs introduced on 1 April 2010. As a result of this, health insurance companies would pay the same amount for drugs with the same active ingredient, adjusted to the price of the cheapest alternative.
Plans announced for future changes are in step with these prior activities. According to PMR estimates, the generic drug market will, therefore, develop at a CAGR in excess of 6% between 2011 and 2013, whereas original drugs will grow at a rate of 4% during the period in question.

Poland: will legal regulations hamper innovation?
As clinical trials are one of the main modes of access to the most innovative medicines for Polish patients, it is quite easy to recruit clinical trial participants in Poland, in comparison with other countries. The potential of clinical trials in Poland is, however, not used to the full, as a similar number of trials (450-500 per annum) are carried out in, for example, Hungary and the Czech Republic, countries with smaller populations. One of the reasons for this is the ambiguous legislation, which, is one of the most obstructive obstacles to the development of companies operating on the Polish clinical trials market.
There is no single legal act in force in Poland, which would regulate the clinical research market comprehensively. The relevant provisions pertaining to the clinical trials market are contained in various legal acts of various categories, including those relating solely to the pharmaceutical market (e.g. the Pharmaceutical Law), but also the Civil Code and the Penal Code. It is also worthy of note that provisions of various acts are frequently inconsistent with each other.
Another problem is VAT applied on clinical trials. In these area Poland has still not harmonised its legislation with the European Union directives. Pursuant to the so-called VI EU Directive, expert services, including clinical research, should be subject to taxation only in the country of the client; nevertheless, most companies operating in Poland pay 23% VAT as the monitoring of clinical trials, according to the effective statistical classification can be classified into four different groups of services and which group it is categorised under depends on the civil servant’s interpretation.
Improvement in these areas would not only lead to an increase in the number of clinical trials conducted by international concerns in Poland (which would improve patient access to innovations) but could also encourage domestic manufacturers to invest in innovative medicines. This could, in the longer term, prompt an increase in the share of innovative medicines as a proportion of the Polish pharmaceutical market, which is one of the leas substantial in Central Europe.

Hungary: R&D expenditures no longer tax-deductable
A Hungarian government proposal suggests that drug manufacturers in Hungary will no longer be able to deduct their R&D expenses from the fee of the medical sales representative and the 12% tax on revenues from reimbursed drugs paid to the National Health Insurance Fund (OEP). The legislative changes could constitute a burden for some of the largest drug manufacturers on the Hungarian pharmaceutical market. This could also adversely affect manufacturers of innovative drugs, which may, as a result, reduce their R&D spending. The deduction was introduced in 2009, when 20% of the R&D costs could have been subtracted from the expenditures, and this was increased to 100% in 2010.
The Hungarian government is also planning to change the existing system which involves obligatory courses for doctors who allegedly prescribe excessively expensive medicines. It hopes, instead, to convince doctors to prescribe cheaper generic drugs, thus saving public money by establishing an incentive system. Furthermore, pharmacists would also be involved and rewarded when they replace a prescribed medicine with the product with the lowest reimbursement level.

Slovakia: reimbursement reform to boost generic consumption
After an allegation that the Categorisation Committee lacked transparency, the Slovak Health Ministry has decided to make drug policy more open and the individual steps within the categorisation process of drug reimbursement more transparent. Several regulations pertaining to the drug reimbursement system could come into force in Slovakia in 2011.
The proposed changes in the area of generic and innovative medicines include the earlier appearance of generics and conditional drug categorisation, along with the introduction of API prescription by doctors.
The proposed changes will allow the submission of applications for the categorisation of new drugs before a decision on their registration has been made. As a result, the assessment of applications for registration and categorisation will be carried out simultaneously. The ministry believes that this move will accelerate the arrival of cheaper generics on the market and save about €5m per annum.
The Health Ministry is also considering the introduction of new regulations which will stipulate that doctors in Slovakia should prescribe only the active pharmaceutical ingredient (API) instead of the specific drug name. A pharmacist would then advise patients on the drugs available, particularly those which carry the lowest co-payments, and patients would take the final decision. The new system would not cover all drugs – cancer and psychiatric medication would still be a matter for the doctor. At the moment, the schedule for the introduction of the new prescription system is not clear.

This press release is based on information contained in the latest PMR report entitled "Generic and innovative drugs market in Central Europe 2011. Comparative analysis, reimbursement policies and development forecasts for 2011-2013".

PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research). Being present on the market since 1995, employing highly skilled staff, offering high international standards in projects and publications, providing one of most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.

PMR Publications
ul. Dekerta 24, 30-703 Krakow, Poland
tel. /48/ 12 618 90 00, fax /48/ 12 618 90 08
Contact Person: Anna Rojek, marketing@pmrcorporate.com
www.pmrpublications.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generic drug market in Central Europe will grow by 6% per annum between 2011 and 2013 here

News-ID: 162433 • Views:

More Releases from PMR Ltd. Sp. z o.o.

OTC market in Central and Eastern Europe will exceed EUR 12bn in 2012
OTC market in Central and Eastern Europe will exceed EUR 12bn in 2012
The economic downturn affected the market of OTC products in Central and Eastern Europe which in 2009 grow by only 1% y-o-y in euro terms. In the following years, between 2010 and 2012 the growth rate will be higher, and the market will grow at CAGR of around 10% to EUR 12bn in 2012, according to the latest report from PMR, a research and consulting company, entitled "OTC market in
Russian telecommunications market – moderate forecasts for 2011
Russian telecommunications market – moderate forecasts for 2011
The value of the Russian telecommunications services market will increase 5% this year. Forecasts for 2011 are only slightly better and rather cautious. The overall performance of the Russian economy will continue to play an important role for the country's telecoms industry. In recent years, the Russian telecommunications market has demonstrated strong growth, driven by the country's continuing strong economic performance. Until 2009, Russia experienced more than ten years of
Grocery market in Central Europe to grow to EUR 102.8bn in 2010
Grocery market in Central Europe to grow to EUR 102.8bn in 2010
The grocery market in five Central European countries, the Czech Republic, Hungary, Poland, Romania and Slovakia, was worth app.EUR100bn in 2009, according to the latest report from PMR, a research and consulting company, entitled "Grocery retail in Central Europe 2010. Market analysis and development forecasts for 2010-2012". Last year, the worsened economic conditions negatively affected the grocery market in the region, with Poland being the only country reporting an increase of

All 4 Releases


More Releases for Poland

Poland Agriculture Market, Poland Agriculture Industry, Agriculture Livestock Ma …
Poland is a significant European and global producer of numerous agricultural products. The agricultural land market in country is divided in two parts: privately owned farms and land owned farms by the State Treasury. Privately owned farm is an enterprise to cultivate various agricultural products under the control of one or more investor. Poland is among the world's primary producers of potatoes, rye, and apples, as well as pork and
MAUSER Poland Celebrates 5th Anniversary
Bruehl/Germany, June 27, 2017 MAUSER Group, a worldwide leading company in industrial packaging, celebrates the 5th anniversary of its factory in Gliwice, Poland. Ideally located in the industrial heartland of Upper Silesia, and operated by a strong local management team, the plant offers high-quality industrial packaging solutions and services. MAUSER Poland serves customers with a comprehensive product range of Composite Intermediate Bulk Containers (CIBCs) and plastic tight-head drums. In line with
Agrochemicals Market in Poland
ReportsWorldwide has announced the addition of a new report title Poland: Agrochemicals: Market Intelligence (2016-2021) to its growing collection of premium market research reports. The report “Poland: Agrochemicals: Market Intelligence (2016-2021)” provides market intelligence on the different market segments, based on type, active ingredient, formulation, crop, and pest. Market size and forecast (2016-2021) has been provided in terms of both, value (000 USD) and volume (000 KG) in the report. A
A+ ratings on Poland
Jelenia Gora/Poland, 20.09.2011 - In August 2011 two rating agencies i.e. Standard & Poor's and Moody's Investors Service affirmed their A+ rating on Poland with a stable outlook. Both agencies noted that the Polish economy is competitive and increasingly diversified. Moody's evaluated Poland as relatively well placed to withstand global turmoil with its relatively resilient economy. Both agencies stressed that the Polish economy continued to expand in 2009, in contrast
IT market in Poland
IT providers in Poland are starting the post-crisis period in actually quite good moods and are already beginning to predict what solutions will be most sought after by their customers during prosperity. However last year hardware distributors recorded significant reduction in the number of orders placed, especially by business customers, software and IT services providers performed far better. A majority of them had similar sales as in previous periods, while some
VoIP in Poland
At the end of 2008 the Polish VoIP telephony market was worth PLN 440m, with CaTV operators having generated the largest share of revenue in the segment. In recent years also fixed-line operators have included VoIP services into their offer. According to research and consulting company PMR Polish VoIP market continues to represent a small share of the fixed-line telecommunications market. In 2008 it accounted for approximately five percent of the